Selway Asset Management Gilead Sciences, Inc. Transaction History

Selway Asset Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 22, 2020	SELL	$62.63 - $80.22 $569,933 - $730,002	-9,100 Closed	0 $0
Q4 2019 Jan 23, 2020	SELL	$61.62 - $67.78 $44,674 - $49,140	-725 Reduced 7.38%	9,100 $591,000
Q2 2019 Jul 30, 2019	SELL	$61.87 - $69.38 $12,374 - $13,876	-200 Reduced 2.0%	9,825 $664,000
Q1 2019 Apr 18, 2019	SELL	$62.53 - $70.05 $151,635 - $169,871	-2,425 Reduced 19.48%	10,025 $652,000
Q4 2018 Jan 30, 2019	SELL	$60.54 - $79.0 $12,108 - $15,800	-200 Reduced 1.58%	12,450 $779,000
Q3 2018 Oct 30, 2018	SELL	$71.28 - $78.92 $235,224 - $260,436	-3,300 Reduced 20.69%	12,650 $977,000
Q2 2018 Jul 24, 2018	SELL	$64.88 - $75.68 $110,295 - $128,656	-1,700 Reduced 9.63%	15,950 $1.13 Million
Q1 2018 Apr 23, 2018	SELL	$72.84 - $88.8 $145,680 - $177,600	-2,000 Reduced 10.18%	17,650 $1.33 Million
Q4 2017 Jan 31, 2018	SELL	$71.15 - $83.52 $170,760 - $200,448	-2,400 Reduced 10.88%	19,650 $1.41 Million
Q3 2017 Oct 24, 2017	BUY	$72.11 - $85.47 $1.59 Million - $1.88 Million	22,050	22,050 $1.79 Million

1,879

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Selway Asset Management, based on Form 13F filings with the SEC.

Stay updated on Selway Asset Management with notifications on news.